+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006-2008



Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006-2008



Diabetic Medicine 31(6): 640-646



To describe characteristics associated with statin prescribing for the primary prevention of cardiovascular disease in people with newly diagnosed diabetes. Data from the Scottish Care Information-Diabetes Collaboration data set for 2006-2008 were used. This data set contains socio-demographic and prescribing data for over 99% of people with diagnosed diabetes in Scotland. Analyses were conducted on people aged over 40 years diagnosed with Type 1 or Type 2 diabetes between 2006 and 2008 with complete data and no previous history of cardiovascular or statin prescription. Logistic regression was used to calculate odds ratios for statin prescription in the 2 years following diagnosis of diabetes. There were 7157 men and 5601 women who met the inclusion criteria, 68% of whom had a statin prescription recorded in the 2 years following diagnosis of diabetes. The proportions receiving statins were lower above 65 years of age in men and 75 years of age in women. People with Type 1 diabetes had lower odds of receiving statins than people with Type 2 diabetes [odds ratio (95% CI) 0.42 (0.29-0.61) for men and 0.48 (0.28-0.81) for women, after adjustment for age, BMI, smoking status, cholesterol level and deprivation]. Higher total cholesterol, BMI and being a current smoker were associated with greater odds of statin prescription. Approximately one third of the study population had no record of statin prescription during the 2 years after diagnosis of diabetes. Cardiovascular disease risk reduction opportunities may be missed in some of these people.

(PDF emailed within 0-6 h: $19.90)

Accession: 053194630

Download citation: RISBibTeXText

PMID: 24533646

DOI: 10.1111/dme.12409


Related references

Statin for the primary prevention of cardiovascular disease in patients with diabetes mellitus. Diabetes & Metabolism Journal 38(1): 32-34, 2014

Primary prevention of cardiovascular disease with statin in type 2 diabetes mellitus: Is it time to change our strategy?. Medicina Clinica 142(8): 358-359, 2014

Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study. Cardiovascular Diabetology 15(1): 147-147, 2016

Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. Indian Journal of Medical Research 138(4): 461-491, 2015

Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. Circulation 133(16): 1574-1581, 2016

Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?. Medical Journal of Australia 190(11): 614-615, 2009

Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly. Cardiovascular Drugs and Therapy 29(2): 187-197, 2016

Predictors of cholesterol treatment discussions and statin prescribing for primary cardiovascular disease prevention in community health centers. Preventive Medicine 88(): 176-181, 2016

Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 369(9556): 107-114, 2007

Coronary heart disease and cardiovascular risk factors among people aged 25-65 years, as seen in Romanian primary healthcare. European Journal of General Practice 14(2): 56-64, 2008

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. European Heart Journal 35(5): 290-298, 2014

Impact of Statin Adherence on Cardiovascular Morbidity and All-Cause Mortality in the Primary Prevention of Cardiovascular Disease: A Population-Based Cohort Study in Finland. Value in Health 18(6): 896-905, 2016

Statin therapy for primary prevention of cardiovascular disease. JAMA 310(22): 2451-2452, 2013

Statin in the primary and secondary prevention of cardiovascular disease. Nihon Rinsho. Japanese Journal of Clinical Medicine 74 Suppl 4 Pt 1: 556-561, 2016

Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. American Diabetes Association. Diabetes Care 12(8): 573-579, 1989